Submission date
03/03/2006
Registration date
31/03/2006
Last edited
18/04/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Retrospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration and not expected to be available in the future

Study website

Contact information

Type

Scientific

Contact name

Prof René Rizzoli

ORCID ID

Contact details

Hôpital Cantonal de Genève
Département de Réhabilitation et Gériatrie
Service des Maladies Osseuses
24
Rue Micheli–du-Crest
Geneve 14
1211
Switzerland

Additional identifiers

EudraCT/CTIS number

2006-002732-22

IRAS number

ClinicalTrials.gov number

Protocol/serial number

CL3-12911-019

Study information

Scientific title

A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)

Acronym

Study hypothesis

To demonstrate the effects of strontium ranelate on bone microarchitecture in women with postmenopausal osteoporosis in comparison with marketed bisphosphonates.

On 27/11/2012 the anticipated end date for this trial was updated from 31/10/2007 to 28/02/2008.

Ethics approval(s)

First Ethics Committee approval obtained on 21/09/2005 in France, ref: 2005-064-2

Study design

Double-blind randomised controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Post-menopausal osteoporosis

Intervention

Strontium ranelate (S12911) versus marketed bisphosphonates.

Intervention type

Drug

Pharmaceutical study type(s)

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Bisphosphonates, strontium ranelate

Primary outcome measure

Assessment of trabecular bone volume to tissue volume

Secondary outcome measures

Assessment of bone density, bone structure and bone markers

Overall study start date

31/10/2005

Overall study end date

28/02/2008

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Women of at least 50 years old
2. Postmenopausal for at least five years
3. Osteoporosis

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

72

Participant exclusion criteria

1. Body mass index (BMI) <18 or >30 kg/m^2
2. Skeletal disease
3. Severe malabsorption
4. Significant and evolutive hyperthyroidism

Recruitment start date

31/10/2005

Recruitment end date

28/02/2008

Locations

Countries of recruitment

Australia, France, Germany, Switzerland

Study participating centre

Hôpital Cantonal de Genève
Geneve 14
1211
Switzerland

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

Sponsor details

50 rue Carnot
Suresnes
92284
France

Sponsor type

Industry

Website

http://www.servier.com/

ROR

https://ror.org/034e7c066

Funders

Funder type

Industry

Funder name

Institut de Recherches Internationales Servier (France)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Current version as of 28/03/2018:
Summary results are published in https://clinicaltrials.servier.com.
For interventional Phase III studies ending after the 1st January 2014, the results are/will be published in scientific literature.

IPD sharing plan: The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

Previous version as of 24/01/2018:
Publication plan:
All phases - Interventional studies ending before 01/10/2018: Summary results will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study.
All phases - Interventional studies ending after 01/10/2018: Summary results and a lay summary will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study.
Phase 3 only - The results will be published in scientific literature within 18 months after the end of the study.

Intention to publish date

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com/ if a Marketing Authorisation has been granted after 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results No No
Results article results 01/08/2010 Yes No

Additional files

Editorial Notes

18/04/2018: Internal review 28/03/2018: The publication and dissemination plan has been changed. 24/01/2018: Publication plan and IPD sharing statement added. 06/12/2017: results summary added.